Medical Devices Startups

Xenoma develops e-skin, a washable garment-type IoT device embedded with stretchable sensors that measures healthcare data when worn. The company uses this technology for at-home medical testing services, including a 3-lead Holter electrocardiogram mailed for home use, aiming at preventive care for cardiovascular and other diseases.

2 investors

Cardio Intelligence develops AI-based electrocardiogram analysis software as medical device programs, including its SmartRobin AI long-term ECG analysis series and SmartPAFin software for detecting signs of paroxysmal atrial fibrillation. The company is a licensed medical device manufacturer and distributor based in Tokyo, Japan.

2 investors

Kino Pharma is a Japan-based company with a Tokyo headquarters and a Kyoto research laboratory. The page provides only corporate location information and does not describe the company's products or services.

2 investors

TWOCELLS (株式会社ツーセル) is a regenerative medicine venture developing therapies and products based on mesenchymal stem cells (MSCs), including its gMSC series for cartilage regeneration, along with serum-free culture media (STK series) and consulting services. Founded as a Hiroshima University spin-off, it also licenses its technology to pharmaceutical partners.

2 investors

MedRx is a Japanese pharmaceutical company developing new drugs based on transdermal delivery technologies such as its ILTS and NCTS platforms and microneedle arrays. It is a publicly listed company focused on creating novel therapeutics for patients with various diseases.

2 investors

Rehasaku provides cloud-based rehabilitation and physical therapy management systems for medical institutions and treatment clinics in Japan. The platform includes exercise therapy management, guidance support tools, AI-powered posture analysis, appointment scheduling, and web marketing support.

2 investors

Kyoto Drug develops novel therapeutic drugs for rare and difficult-to-treat ocular diseases including retinal artery occlusion and retinitis pigmentosa, using a new small-molecule compound (KUS agent) based on research from Kyoto University.

2 investors

Alivas is a medical device startup developing a new therapeutic device for refractory chronic constipation, a condition affecting patients who do not respond to drug treatment. The company originated from the Japan Biodesign program, a collaboration between Stanford University and the University of Tokyo.

1 investor

Epsilon Medical develops and manufactures intravascular electrodes for cerebrovascular applications. The company operates in the medical device sector, serving clinical and research markets.

1 investor

TL Genomics develops in vitro diagnostic medical products and healthcare testing services, focusing on bone marrow transplant testing, chromosome analysis for disease risk and fertility assessment, and related medical services.

1 investor

Cellusion is a regenerative medicine company developing innovative technologies and products based on patient-centric research across disease areas where regenerative medicine can create new therapeutic value.

1 investor

1928 Diagnostics provides a cloud-based bioinformatics platform that transforms complex genomic sequencing data into actionable insights for researchers, healthcare providers, and organizations. The platform automates genomic analysis workflows, making advanced analytics accessible without requiring specialized computational expertise or on-site infrastructure.

1 investor

19Labs builds GALE, a smart point-of-care platform that brings a full clinic experience to schools, rural communities, and pharmacies. The company focuses on providing telemedicine and healthcare access to underserved rural populations worldwide.

1 investor

1nhaler develops a single-dose dry powder inhaler made mostly from cardboard, designed to be low-cost, portable, propellant-free and low in carbon impact for delivering inhalable medicines. Its lead project is a salbutamol inhaler for asthma relief, with potential applications in rescue medications, anaphylaxis, migraine, vaccines and clinical trials.

1 investor

2AB BioscienceS develops first-in-class small molecule therapeutics targeting the 5-HT2A receptor for ophthalmology and central nervous system disorders. The platform uses structure-guided design to create therapies aimed at tissue regeneration, inflammation resolution, and neural circuit restoration.

1 investor

2bull MeDiTherapy develops in-vitro diagnostic medical devices, including TAP, a blood test designed to detect thoracic and abdominal aortic aneurysms. The company focuses on early detection and monitoring diagnostics for cardiovascular disease.

1 investor

2cureX develops IndiTreat®, a 3D functional precision medicine test that grows patient-derived cancer cells as 3D microtumors (tumoroids) from a tumor biopsy to profile drug sensitivity and guide individualized therapy selection. The company serves oncologists and healthcare professionals, providing drug-response reports to inform cancer treatment decisions, and brings its diagnostic products through EU regulatory and reimbursement pathways.

1 investor

2EyesVision develops ophthalmic simulation technology for patients to experience presbyopic and cataract corrections before surgery. The company commercializes medical devices and software solutions addressing age-related vision conditions affecting large patient populations globally.

1 investor

A biotech company focused on microbiome and metabolomics research for gastrointestinal health applications, with leadership and scientific advisory rooted in academic medicine and regulatory expertise.

1 investor

3Brain develops microchip-based technology for recording and analyzing cell activity in life science research, combining microelectronics with biology to enable precise real-time monitoring of electrogenic cells. The company serves researchers in academia and industry, operating in the bioelectronics and life sciences sector.

1 investor

3C Therapeutics develops therapeutics using targeted protein degradation, centered on a proprietary modular Degrader-Antibody Conjugate (DAC) platform (TriCore) that delivers intracellular protein degraders via monoclonal antibodies. The company focuses on drug discovery for previously inaccessible targets through a ligand-independent conjugation approach.

1 investor

3D-Side develops a web-based platform called Customize that connects surgeons, patients, and medical device manufacturers to plan, design, and supervise production of patient-specific medical devices for surgical applications. The Belgian company originated as a university spin-off and serves the medical technology and 3D printing sectors.

1 investor

3D OrthoBiologic Solutions develops and commercializes 3D-printed bone graft scaffolds for surgery and 3D cell culture technologies, targeting the treatment of bone defects and diseases. Its work focuses on orthopedic and oral/maxillofacial reconstructive and regenerative medicine.

1 investor

3Helix develops and sells collagen hybridizing peptides (CHP) and related conjugates for research and diagnostic applications. The company's products are designed to detect and bind denatured collagen chains in both laboratory and in vivo settings.

1 investor